Professor David Burden

  • Honorary Professor (Institute of Infection Immunity & Inflammation)

email: David.Burden@glasgow.ac.uk

Department of Dermatology, Western Infirmary

Publications

List by: Type | Date

Jump to: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2009 | 2007 | 2005
Number of items: 43.

2021

Becher, G. and Burden, A.D. (2021) Psoriasis, COVID-19 and shielding. British Journal of Dermatology, 185(1), pp. 7-8. (doi: 10.1111/bjd.20055) (PMID:33951179) (PMCID:PMC8239873)

O’Shaughnessy, E. M., Duffy, W., Garcia-Vega, L., Hussey, K., Burden, A. D., Zamiri, M. and Martin, P. E. (2021) Dysregulation of connexin expression plays a pivotal role in psoriasis. International Journal of Molecular Sciences, 22(11), 6060. (doi: 10.3390/ijms22116060) (PMCID:PMC8200029)

2020

Warren, R.B., Barker, J.N.W.B., Finlay, A.Y., Burden, A.D., Kirby, B., Armendariz, Y., Williams, R., Hatchard, C., Khare, S. and Griffiths, C.E.M. (2020) Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE). British Journal of Dermatology, 183(1), pp. 60-70. (doi: 10.1111/bjd.18623) (PMID:31628677)

Mahil, S.K. et al. (2020) Psoriasis treat to target: defining outcomes in psoriasis using data from a real world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). British Journal of Dermatology, 182(5), pp. 1158-1166. (doi: 10.1111/bjd.18333) (PMID:31286471) (PMCID:PMC7317460)

Rungapiromnan, W. et al. (2020) Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34(4), pp. 769-778. (doi: 10.1111/jdv.16018) (PMID:31633837)

Cro, S. et al. (2020) A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. Trials, 21, 158. (doi: 10.1186/s13063-020-4103-z) (PMID:32041649) (PMCID:PMC7011285)

Pan, S. et al. (2020) Using real‐world data to guide ustekinumab dosing strategies for psoriasis: a prospective pharmacokinetic‐pharmacodynamic study. Clinical and Translational Science, 13(2), pp. 400-409. (doi: 10.1111/cts.12725) (PMID:31995663) (PMCID:PMC7070790)

2019

Yiu, Z.Z.N., Mason, K.J., Barker, J.N.W.N., Hampton, P.J., McElhone, K., Smith, C.H., Warren, R.B., Griffiths, C.E.M., Lunt, M. and Burden, A.D. (2019) A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis. British Journal of Dermatology, 181(6), pp. 1265-1271. (doi: 10.1111/bjd.17849) (PMID:30822358)

Dand, N. et al. (2019) HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143(6), pp. 2120-2130. (doi: 10.1016/j.jaci.2018.11.038) (PMID:30578879)

Mrowietz, U., Bachelez, H., Burden, A. D., Rissler, M., Sieder, C., Orsenigo, R. and Chaouche-Teyara, K. (2019) Secukinumab for moderate to severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. Journal of the American Academy of Dermatology, 80(5), pp. 1344-1352. (doi: 10.1016/j.jaad.2019.01.066) (PMID:30716404)

Warren, R.B. et al. (2019) Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180(5), pp. 1069-1076. (doi: 10.1111/bjd.16776) (PMID:30155885) (PMCID:PMC6519065)

Twelves, S. et al. (2019) Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology, 143(3), pp. 1021-1026. (doi: 10.1016/j.jaci.2018.06.038) (PMID:30036598) (PMCID:PMC6403101)

Wilkinson, N. et al. (2019) Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. Journal of Investigative Dermatology, 139(1), pp. 115-123. (doi: 10.1016/j.jid.2018.07.028) (PMID:30130616) (PMCID:PMC6300405)

Tsakok, T. et al. (2019) Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatology, 155(11), pp. 1235-1243. (doi: 10.1001/jamadermatol.2019.1783)

2018

Petridis, C. et al. (2018) Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne. Nature Communications, 9(1), 5075. (doi: 10.1038/s41467-018-07459-5) (PMID:30542056) (PMCID:PMC6290788)

Shams, K., Kurowska-Stolarska, M. , Schütte, F., Burden, A. D., McKimmie, C. S. and Graham, G. J. (2018) MicroRNA-146 and cell trauma down-regulate expression of the psoriasis-associated atypical chemokine receptor ACKR2. Journal of Biological Chemistry, 293(8), pp. 3003-3012. (doi: 10.1074/jbc.M117.809780) (PMID:29279330) (PMCID:PMC5827444)

2017

Dand, N. et al. (2017) Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Human Molecular Genetics, 26(21), pp. 4301-4313. (doi: 10.1093/hmg/ddx328) (PMID:28973304)

Navarini, A. A., Burden, A. D., Capon, F., Mrowietz, U., Puig, L., Köks, S., Kingo, K., Smith, C. and Barker, J. N. (2017) European consensus statement on phenotypes of pustular psoriasis. Journal of the European Academy of Dermatology and Venereology, 31(11), pp. 1792-1799. (doi: 10.1111/jdv.14386) (PMID:28585342)

Burden, A.D. (2017) Etanercept or infliximab for psoriasis? An independent randomized clinical trial. British Journal of Dermatology, 176(3), p. 565. (doi: 10.1111/bjd.15160) (PMID:28300301)

Graham, G. et al. (2017) Spread of psoriasiform inflammation to remote tissues is restricted by the atypical chemokine receptor ACKR2. Journal of Investigative Dermatology, 137(1), pp. 85-94. (doi: 10.1016/j.jid.2016.07.039) (PMID:27568525) (PMCID:PMC5176004)

2016

Mahil, S. K. et al. (2016) AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. Journal of Investigative Dermatology, 136(11), pp. 2251-2259. (doi: 10.1016/j.jid.2016.06.618)

Krishnadas, R. et al. (2016) Circulating Tumour Necrosis Factor is highly correlated with brainstem serotonin transporter availability in humans. Brain, Behavior, and Immunity, 51, pp. 29-38. (doi: 10.1016/j.bbi.2015.08.005) (PMID:26255693)

2015

Griffiths, C. E. M., Barnes, M. R., Burden, A. D., Nestle, F. O., Reynolds, N. J., Smith, C. H., Warren, R. B. and Barker, J. N. W. N. (2015) Establishing an academic–industrial stratified medicine consortium: psoriasis stratification to optimize relevant therapy. Journal of Investigative Dermatology, 135(12), pp. 2903-2907. (doi: 10.1038/jid.2015.286) (PMID:26569580)

Warren, R. B. et al. (2015) Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British association of dermatologists biologic interventions register (BADBIR). Journal of Investigative Dermatology, 135(11), pp. 2632-2640. (doi: 10.1038/jid.2015.208) (PMID:26053050)

Iskandar, I.Y.K. et al. (2015) Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. British Journal of Dermatology, 173(2), pp. 510-518. (doi: 10.1111/bjd.13908) (PMID:25989336)

2014

Coates, L. C. et al. (2014) Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. Arthritis Care and Research, 66(9), pp. 1410-1416. (doi: 10.1002/acr.22284)

Setta-Kaffetzi, N. et al. (2014) AP1S3 mutations are associated with pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. American Journal of Human Genetics, 94(5), pp. 790-797. (doi: 10.1016/j.ajhg.2014.04.005)

Coates, L.C. et al. (2014) Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. British Journal of Dermatology, 170(4), pp. 995-996. (doi: 10.1111/bjd.12824)

Navarini, A. A. et al. (2014) Genome-wide association study identifies three novel susceptibility loci for severe Acne vulgaris. Nature Communications, 5, p. 4020. (doi: 10.1038/ncomms5020)

2012

Singh, M.D. et al. (2012) Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis. American Journal of Pathology, 181(4), pp. 1158-1164. (doi: 10.1016/j.ajpath.2012.06.042) (PMID:22867710) (PMCID:PMC3532592)

Becher, G. and Burden, A.D. (2012) Understanding the variation in response to methotrexate. British Journal of Dermatology, 167(1), pp. 2-3. (doi: 10.1111/j.1365-2133.2012.11028.x)

Capon, F., Burden, A.D., Trembath, R.C. and Barker, J.N. (2012) Psoriasis and other complex trait dermatoses: from loci to functional pathways. Journal of Investigative Dermatology, 132(3), pp. 915-922. (doi: 10.1038/jid.2011.395)

Onoufriadis, A., Simpson, M.A., Burden, A.D., Barker, J.N., Trembath, R.C. and Capon, F. (2012) Identification of rare, disease-associated variants in the promoter region of the RNF114 psoriasis susceptibility gene. Journal of Investigative Dermatology, 132(4), pp. 1297-1299. (doi: 10.1038/jid.2011.431)

2011

Onoufriadis, A. et al. (2011) Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. American Journal of Human Genetics, 89(3), pp. 432-437. (doi: 10.1016/j.ajhg.2011.07.022)

Wylie, G., Makrygeorgou, A. and Burden, A.D. (2011) Buccal prochlorperazine causing perioral fixed drug eruption. Clinical and Experimental Dermatology, 36(6), pp. 672-673. (doi: 10.1111/j.1365-2230.2011.04020.x)

Burden, A.D. (2011) Drug survival rates for tumour necrosis factor-α antagonists in psoriasis. British Journal of Dermatology, 164(5), pp. 940-941. (doi: 10.1111/j.1365-2133.2011.10355.x)

Laws, P.M. et al. (2011) Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. British Journal of Dermatology, 166(1), pp. 189-195. (doi: 10.1111/j.1365-2133.2011.10638.x)

Tziotzios, C. and Burden, D. (2011) Swelling scars. QJM: An International Journal of Medicine, 104(5), pp. 445-446. (doi: 10.1093/qjmed/hcq040)

Wylie, G.R. and Burden, D. (2011) Renbok phenomenon between psoriasis and alopecia areata. Clinical and Experimental Dermatology, 36(7), pp. 816-817. (doi: 10.1111/j.1365-2230.2011.04097.x)

2009

Al-Niaimi, F., Jury, C., Burden, D. and Mealyea, M. (2009) Changing patterns of zoophilic fungal infections in the West of Scotland illustrated by two cases of tinea corporis from domestic rodents. Clinical and Experimental Dermatology, 34(8), pp. 925-926. (doi: 10.1111/j.1365-2230.2008.03101.x)

May, C., Burden, D., Palmer, M. and Leman, J. (2009) Peyronie's disease associated with methotrexate therapy. Clinical and Experimental Dermatology, 34(7), e467-e468.

2007

Zhao, Y. et al. (2007) Filaggrin null alleles are not associated with psoriasis. Journal of Investigative Dermatology, 127, pp. 1878-1882. (doi: 10.1038/sj.jid.5700817)

2005

Abecasis, G. et al. (2005) Fine mapping of the psoriasis susceptibility gene PSORS1: A reassessment of risk associated with a putative risk haplotype lacking HLA-Cw6. Journal of Investigative Dermatology, 124, pp. 921-930. (doi: 10.1111/j.0022-202X.2005.23729.x)

This list was generated on Sat Oct 16 15:22:09 2021 BST.
Jump to: Articles
Number of items: 43.

Articles

Becher, G. and Burden, A.D. (2021) Psoriasis, COVID-19 and shielding. British Journal of Dermatology, 185(1), pp. 7-8. (doi: 10.1111/bjd.20055) (PMID:33951179) (PMCID:PMC8239873)

O’Shaughnessy, E. M., Duffy, W., Garcia-Vega, L., Hussey, K., Burden, A. D., Zamiri, M. and Martin, P. E. (2021) Dysregulation of connexin expression plays a pivotal role in psoriasis. International Journal of Molecular Sciences, 22(11), 6060. (doi: 10.3390/ijms22116060) (PMCID:PMC8200029)

Warren, R.B., Barker, J.N.W.B., Finlay, A.Y., Burden, A.D., Kirby, B., Armendariz, Y., Williams, R., Hatchard, C., Khare, S. and Griffiths, C.E.M. (2020) Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE). British Journal of Dermatology, 183(1), pp. 60-70. (doi: 10.1111/bjd.18623) (PMID:31628677)

Mahil, S.K. et al. (2020) Psoriasis treat to target: defining outcomes in psoriasis using data from a real world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). British Journal of Dermatology, 182(5), pp. 1158-1166. (doi: 10.1111/bjd.18333) (PMID:31286471) (PMCID:PMC7317460)

Rungapiromnan, W. et al. (2020) Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34(4), pp. 769-778. (doi: 10.1111/jdv.16018) (PMID:31633837)

Cro, S. et al. (2020) A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. Trials, 21, 158. (doi: 10.1186/s13063-020-4103-z) (PMID:32041649) (PMCID:PMC7011285)

Pan, S. et al. (2020) Using real‐world data to guide ustekinumab dosing strategies for psoriasis: a prospective pharmacokinetic‐pharmacodynamic study. Clinical and Translational Science, 13(2), pp. 400-409. (doi: 10.1111/cts.12725) (PMID:31995663) (PMCID:PMC7070790)

Yiu, Z.Z.N., Mason, K.J., Barker, J.N.W.N., Hampton, P.J., McElhone, K., Smith, C.H., Warren, R.B., Griffiths, C.E.M., Lunt, M. and Burden, A.D. (2019) A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis. British Journal of Dermatology, 181(6), pp. 1265-1271. (doi: 10.1111/bjd.17849) (PMID:30822358)

Dand, N. et al. (2019) HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143(6), pp. 2120-2130. (doi: 10.1016/j.jaci.2018.11.038) (PMID:30578879)

Mrowietz, U., Bachelez, H., Burden, A. D., Rissler, M., Sieder, C., Orsenigo, R. and Chaouche-Teyara, K. (2019) Secukinumab for moderate to severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. Journal of the American Academy of Dermatology, 80(5), pp. 1344-1352. (doi: 10.1016/j.jaad.2019.01.066) (PMID:30716404)

Warren, R.B. et al. (2019) Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180(5), pp. 1069-1076. (doi: 10.1111/bjd.16776) (PMID:30155885) (PMCID:PMC6519065)

Twelves, S. et al. (2019) Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology, 143(3), pp. 1021-1026. (doi: 10.1016/j.jaci.2018.06.038) (PMID:30036598) (PMCID:PMC6403101)

Wilkinson, N. et al. (2019) Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. Journal of Investigative Dermatology, 139(1), pp. 115-123. (doi: 10.1016/j.jid.2018.07.028) (PMID:30130616) (PMCID:PMC6300405)

Tsakok, T. et al. (2019) Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatology, 155(11), pp. 1235-1243. (doi: 10.1001/jamadermatol.2019.1783)

Petridis, C. et al. (2018) Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne. Nature Communications, 9(1), 5075. (doi: 10.1038/s41467-018-07459-5) (PMID:30542056) (PMCID:PMC6290788)

Shams, K., Kurowska-Stolarska, M. , Schütte, F., Burden, A. D., McKimmie, C. S. and Graham, G. J. (2018) MicroRNA-146 and cell trauma down-regulate expression of the psoriasis-associated atypical chemokine receptor ACKR2. Journal of Biological Chemistry, 293(8), pp. 3003-3012. (doi: 10.1074/jbc.M117.809780) (PMID:29279330) (PMCID:PMC5827444)

Dand, N. et al. (2017) Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Human Molecular Genetics, 26(21), pp. 4301-4313. (doi: 10.1093/hmg/ddx328) (PMID:28973304)

Navarini, A. A., Burden, A. D., Capon, F., Mrowietz, U., Puig, L., Köks, S., Kingo, K., Smith, C. and Barker, J. N. (2017) European consensus statement on phenotypes of pustular psoriasis. Journal of the European Academy of Dermatology and Venereology, 31(11), pp. 1792-1799. (doi: 10.1111/jdv.14386) (PMID:28585342)

Burden, A.D. (2017) Etanercept or infliximab for psoriasis? An independent randomized clinical trial. British Journal of Dermatology, 176(3), p. 565. (doi: 10.1111/bjd.15160) (PMID:28300301)

Graham, G. et al. (2017) Spread of psoriasiform inflammation to remote tissues is restricted by the atypical chemokine receptor ACKR2. Journal of Investigative Dermatology, 137(1), pp. 85-94. (doi: 10.1016/j.jid.2016.07.039) (PMID:27568525) (PMCID:PMC5176004)

Mahil, S. K. et al. (2016) AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. Journal of Investigative Dermatology, 136(11), pp. 2251-2259. (doi: 10.1016/j.jid.2016.06.618)

Krishnadas, R. et al. (2016) Circulating Tumour Necrosis Factor is highly correlated with brainstem serotonin transporter availability in humans. Brain, Behavior, and Immunity, 51, pp. 29-38. (doi: 10.1016/j.bbi.2015.08.005) (PMID:26255693)

Griffiths, C. E. M., Barnes, M. R., Burden, A. D., Nestle, F. O., Reynolds, N. J., Smith, C. H., Warren, R. B. and Barker, J. N. W. N. (2015) Establishing an academic–industrial stratified medicine consortium: psoriasis stratification to optimize relevant therapy. Journal of Investigative Dermatology, 135(12), pp. 2903-2907. (doi: 10.1038/jid.2015.286) (PMID:26569580)

Warren, R. B. et al. (2015) Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British association of dermatologists biologic interventions register (BADBIR). Journal of Investigative Dermatology, 135(11), pp. 2632-2640. (doi: 10.1038/jid.2015.208) (PMID:26053050)

Iskandar, I.Y.K. et al. (2015) Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. British Journal of Dermatology, 173(2), pp. 510-518. (doi: 10.1111/bjd.13908) (PMID:25989336)

Coates, L. C. et al. (2014) Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. Arthritis Care and Research, 66(9), pp. 1410-1416. (doi: 10.1002/acr.22284)

Setta-Kaffetzi, N. et al. (2014) AP1S3 mutations are associated with pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking. American Journal of Human Genetics, 94(5), pp. 790-797. (doi: 10.1016/j.ajhg.2014.04.005)

Coates, L.C. et al. (2014) Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. British Journal of Dermatology, 170(4), pp. 995-996. (doi: 10.1111/bjd.12824)

Navarini, A. A. et al. (2014) Genome-wide association study identifies three novel susceptibility loci for severe Acne vulgaris. Nature Communications, 5, p. 4020. (doi: 10.1038/ncomms5020)

Singh, M.D. et al. (2012) Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis. American Journal of Pathology, 181(4), pp. 1158-1164. (doi: 10.1016/j.ajpath.2012.06.042) (PMID:22867710) (PMCID:PMC3532592)

Becher, G. and Burden, A.D. (2012) Understanding the variation in response to methotrexate. British Journal of Dermatology, 167(1), pp. 2-3. (doi: 10.1111/j.1365-2133.2012.11028.x)

Capon, F., Burden, A.D., Trembath, R.C. and Barker, J.N. (2012) Psoriasis and other complex trait dermatoses: from loci to functional pathways. Journal of Investigative Dermatology, 132(3), pp. 915-922. (doi: 10.1038/jid.2011.395)

Onoufriadis, A., Simpson, M.A., Burden, A.D., Barker, J.N., Trembath, R.C. and Capon, F. (2012) Identification of rare, disease-associated variants in the promoter region of the RNF114 psoriasis susceptibility gene. Journal of Investigative Dermatology, 132(4), pp. 1297-1299. (doi: 10.1038/jid.2011.431)

Onoufriadis, A. et al. (2011) Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. American Journal of Human Genetics, 89(3), pp. 432-437. (doi: 10.1016/j.ajhg.2011.07.022)

Wylie, G., Makrygeorgou, A. and Burden, A.D. (2011) Buccal prochlorperazine causing perioral fixed drug eruption. Clinical and Experimental Dermatology, 36(6), pp. 672-673. (doi: 10.1111/j.1365-2230.2011.04020.x)

Burden, A.D. (2011) Drug survival rates for tumour necrosis factor-α antagonists in psoriasis. British Journal of Dermatology, 164(5), pp. 940-941. (doi: 10.1111/j.1365-2133.2011.10355.x)

Laws, P.M. et al. (2011) Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. British Journal of Dermatology, 166(1), pp. 189-195. (doi: 10.1111/j.1365-2133.2011.10638.x)

Tziotzios, C. and Burden, D. (2011) Swelling scars. QJM: An International Journal of Medicine, 104(5), pp. 445-446. (doi: 10.1093/qjmed/hcq040)

Wylie, G.R. and Burden, D. (2011) Renbok phenomenon between psoriasis and alopecia areata. Clinical and Experimental Dermatology, 36(7), pp. 816-817. (doi: 10.1111/j.1365-2230.2011.04097.x)

Al-Niaimi, F., Jury, C., Burden, D. and Mealyea, M. (2009) Changing patterns of zoophilic fungal infections in the West of Scotland illustrated by two cases of tinea corporis from domestic rodents. Clinical and Experimental Dermatology, 34(8), pp. 925-926. (doi: 10.1111/j.1365-2230.2008.03101.x)

May, C., Burden, D., Palmer, M. and Leman, J. (2009) Peyronie's disease associated with methotrexate therapy. Clinical and Experimental Dermatology, 34(7), e467-e468.

Zhao, Y. et al. (2007) Filaggrin null alleles are not associated with psoriasis. Journal of Investigative Dermatology, 127, pp. 1878-1882. (doi: 10.1038/sj.jid.5700817)

Abecasis, G. et al. (2005) Fine mapping of the psoriasis susceptibility gene PSORS1: A reassessment of risk associated with a putative risk haplotype lacking HLA-Cw6. Journal of Investigative Dermatology, 124, pp. 921-930. (doi: 10.1111/j.0022-202X.2005.23729.x)

This list was generated on Sat Oct 16 15:22:09 2021 BST.